The repertoire of peptides presented by a given HLA-I molecule, or immunopeptidome, depends, first of all, on the exceptional polymorphism of HLA genes (96–99), particularly on HLA-I evolutionary divergence: the higher differences of physicochemical properties of amino acids in the peptide-binding groove between two allotypes of the same HLA class I locus, the wider the spectrum of antigenic peptides they present to CD8+ T cells, increasing the chance of an anti-tumor immune response (99). Here, CD8A is linked to neoplasm.